Arcturus adds $50M Meiji investment as Q3 pipeline milestones stay on track
Meiji Seika Pharma bought a stake in Arcturus at a premium to fund OTC deficiency work and validate the LUNAR 2.0 platform, layered onto Q3 trial updates.
SEC filing (5)
3 stories
Meiji Seika Pharma bought a stake in Arcturus at a premium to fund OTC deficiency work and validate the LUNAR 2.0 platform, layered onto Q3 trial updates.
SEC filing (5)
Alector plans an October 13 webinar on its anti-Abeta, tau, and alpha-synuclein programs following its $100 million upfront Genentech license and updated cash guidance into 2029.
SEC filing (5)
The company will lower the exercise price on existing warrants and issue new warrants to holders who agree to exercise, with closing expected September 29, 2026.
SEC filing